Connor Iapoce

Patients with nAMD and their relatives experience a significant burden due to treatment-related time commitments, but most have no issues traveling to the eye clinic.

An analysis in Denmark projects an equal increase in anti-VEGF injections given to patients with RVO and nAMD, with a minor increase for patients with DME.

The risk of diabetic retinopathy appears considerably lower in SGLT2 inhibitor users than in DPP4 inhibitor users among patients with type 2 diabetes.

An update from Apellis reports 10 confirmed events of retinal vasculitis and 2 suspected events associated with pegcetacoplan injection for geographic atrophy.

In a 12-month, real-world study, the implant was effective in more than half of eyes with non-infectious uveitis, achieving effectiveness as soon as 2 weeks post-implantation.

SGLT2 inhibitors added to metformin were associated with a significantly higher risk of diabetic retinopathy progression in the short term but significantly lower risk in the long term.

Faricimab maintained vision improvements and extended treatment intervals up to 4 months for people with RVO in the phase 3 BALATON and COMINO trials.

In a recent case series, a substantial percentage of patients with GA experienced "floaters" from presumed intravitreal silicone oil droplets after pegcetacoplan injection.

New results from the AiDAPT trial show hybrid closed-loop therapy significantly improves maternal glycemic control during pregnancy complicated by T1D.

In our September 2023 cardiology month in review, the editorial team of HCPLive Cardiology highlights a trio of regulatory decision from the FDA and a group of 5 different articles spotlighting data from phase 2 or phase 3 trials.

GLP-1 agonists for weight loss increased the risk of pancreatitis, gastroparesis, and bowel obstruction compared with the use of bupropion-naltrexone.

The latest episode of our mini-docuseries focuses on disparities in ophthalmology, from preventable vision impairment to gaps in access in underserved communities.

Our ophthalmology month in review for September 2023 highlights our top stories in retina, the latest news from the FDA, and insights into the evolving specialty landscape.

A new initiative from the HFSA highlights key findings on heart failure prevalence, risk, mortality and hospitalization rates in the United States.

Phase 1/2 trial data shows all patients with T1D treated with VX-880 achieved improved glycemic control and a reduction or elimination of external insulin needs.

Nondiabetic and diabetic patients without retinopathy experience similar results after treatment with an intravitreal dexamethasone implant for pseudophakic macular edema.

Switching to intravitreal dexamethasone improves visual outcomes, but does not significantly change subfoveal choroidal thickness or the choroidal vascularity index.

The technology could be an important step toward point-of-care diagnostics for microbial keratitis in primary care or other healthcare settings without a laboratory.

Overall quality of life appeared good during the COVID-19 pandemic, but the presence of retinal disease and the number of nonocular comorbidities were linked to negative impacts on vision-related quality of life.

Application of subretinal bevacizumab and tPA effectively removed subretinal hemorrhage secondary to nAMD, but anti-VEGF treatment must be continued.

An analysis of more than 1 million men found higher blood pressure in late adolescence was associated with an increased risk for major cardiovascular events in later life.

Granted a PDUFA date in March 2024, if approved, sotatercept would be a first-in-class medication to address the rare and progressive disease.

According to the approval, the percentage of study eyes returning to ≤0.2 mm from baseline pupil diameter was statistically significantly greater in the phentolamine ophthalmic solution group than placebo.

Type 1 diabetes was diagnosed later for men than women and for racial and ethnic minority adults than non-Hispanic White adults.

Announced by Ionis Pharmaceuticals, topline results show olezarsen met the study's primary endpoint with a statistically significant reduction in triglyceride levels versus placebo.

According to the analysis, high-performing primary care practices use similar strategies to manage change and quality improvement in care for people with diabetes.

Incidental CAC detection on ASCVD risk assessment revealed differences in prevalence by age, sex, and race and ethnicity.

The analysis reports clinical characteristics and the GA progression rate in an Asian population differ from those previously reported in White populations.

Phase 3 results show the non-inferior efficacy of biosimilar liraglutide to the originator in lowering HbA1C over 26 weeks of treatment.

Smartphone measurements were found to be accurate and precise compared with Hertel exophthalmometry or a high-resolution scanner.